- Home
- CRVS vs NPCE Comparison
CRVS vs NPCE Comparison
Compare CRVS & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- NPCE
- Stock Information
- Founded
- CRVS 2014
- NPCE 1997
- Country
- CRVS United States
- NPCE United States
- Employees
- CRVS N/A
- NPCE N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- NPCE Medical Specialities
- Sector
- CRVS Health Care
- NPCE Health Care
- Exchange
- CRVS Nasdaq
- NPCE Nasdaq
- Market Cap
- CRVS 305.4M
- NPCE 292.9M
- IPO Year
- CRVS 2016
- NPCE 2021
- Fundamental
- Price
- CRVS $5.75
- NPCE $9.15
- Analyst Decision
- CRVS Strong Buy
- NPCE Strong Buy
- Analyst Count
- CRVS 4
- NPCE 6
- Target Price
- CRVS $15.00
- NPCE $16.67
- AVG Volume (30 Days)
- CRVS 518.7K
- NPCE 205.3K
- Earning Date
- CRVS 08-07-2025
- NPCE 08-12-2025
- Dividend Yield
- CRVS N/A
- NPCE N/A
- EPS Growth
- CRVS N/A
- NPCE N/A
- EPS
- CRVS N/A
- NPCE N/A
- Revenue
- CRVS N/A
- NPCE $88,570,000.00
- Revenue This Year
- CRVS N/A
- NPCE $22.13
- Revenue Next Year
- CRVS N/A
- NPCE $6.07
- P/E Ratio
- CRVS N/A
- NPCE N/A
- Revenue Growth
- CRVS N/A
- NPCE 23.32
- 52 Week Low
- CRVS $2.54
- NPCE $5.45
- 52 Week High
- CRVS $10.00
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- CRVS 65.10
- NPCE 51.74
- Support Level
- CRVS $5.28
- NPCE $8.61
- Resistance Level
- CRVS $5.64
- NPCE $8.99
- Average True Range (ATR)
- CRVS 0.30
- NPCE 0.53
- MACD
- CRVS 0.03
- NPCE 0.11
- Stochastic Oscillator
- CRVS 77.70
- NPCE 75.00
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.